SCHEMBL17599337

SCHEMBL17599337

Cc1ccc(F)c(S(=O)(=O)Nc2ccc(-c3cccc(C(=O)O)c3)c3ccccc23)c1

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PTK2B Q14289 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
GAA P10253 1/20 0.48
G6PD P11413 1/20 0.48
FABP4 P15090 3/20 0.47
FABP5 Q01469 2/20 0.47
MAP1LC3B Q9GZQ8 1/20 0.46
ACLY P53396 7/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
SLC16A3 O15427 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599317 0.87 FABP4 (0.52) PTK2BSMN1; SMN2KMT2AMEN1GAA
SCHEMBL17599362 0.85 KMT2A (0.46) SMN1; SMN2KMT2AMEN1GAAG6PD
SCHEMBL17599376 0.84 FABP4 (0.56) KMT2AMEN1GAAG6PDFABP4
SCHEMBL17599312 0.84 KEAP1 (0.61) KMT2AMEN1GAA
SCHEMBL17599310 0.84 PTK2B (0.53) PTK2BSMN1; SMN2KMT2AFABP4FABP5
SCHEMBL17599400 0.83 KMT2A (0.49) PTK2BSMN1; SMN2KMT2AFABP4FABP5
SCHEMBL17599342 0.82 FABP4 (0.45) PTK2BSMN1; SMN2KMT2AFABP4FABP5
SCHEMBL17599404 0.82 KMT2A (0.48) KMT2AMEN1GAAG6PDFABP4
SCHEMBL17599319 0.81 ACLY (0.46) PTK2BSMN1; SMN2KMT2AFABP4FABP5
SCHEMBL17599403 0.80 WDR5 (0.49) PTK2BSMN1; SMN2KMT2AMEN1FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed